European Journal of Cancer
Volume 39, Issue 13 , Pages 1948-1956 , September 2003

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

  • L Manenti

      Affiliations

    • Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy
    • ,
  • P Paganoni

      Affiliations

    • Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy
    • ,
  • I Floriani

      Affiliations

    • Laboratory of Clinical Research in Oncology, Department of Oncology, Mario Negri Institute for Pharmacological Research, 20157 Milano, Italy
    • ,
  • F Landoni

      Affiliations

    • Department of Gynecological Oncology, Università degli Studi di Milano-Bicocca, Ospedale San Gerardo dei Tintori, 20052 Monza, Italy
    • ,
  • V Torri

      Affiliations

    • Laboratory of Clinical Research in Oncology, Department of Oncology, Mario Negri Institute for Pharmacological Research, 20157 Milano, Italy
    • ,
  • A Buda

      Affiliations

    • Department of Gynecological Oncology, Università degli Studi di Milano-Bicocca, Ospedale San Gerardo dei Tintori, 20052 Monza, Italy
    • ,
  • G Taraboletti

      Affiliations

    • Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy
    • ,
  • R Labianca

      Affiliations

    • Division of Medical Oncology, Ospedali Riuniti di Bergamo, 24128 Bergamo, Italy
    • ,
  • D Belotti

      Affiliations

    • Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy
    • ,
  • R Giavazzi

      Affiliations

    • Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, via Gavazzeni 11, 24125 Bergamo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-035-319888; fax: +39-035-319331

Received 28 October 2002 ,Revised 5 February 2003 ,Accepted 13 February 2003.

References 

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;47:5–27
  2. Ozols R, Rubin S, Thomas G, Robboy S. Epithelial ovarian cancer. In:  WJ H,  CA P,  RC Y editor. Principles and Practice of Gynecologic Oncology. Baltimore, MD: Lippincott Williams and Wilkins; 2000;p. 981–999
  3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:49–57
  4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31
  5. Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1997;3:1579–1586
  6. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 1998;83:2528–2533
  7. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998;92:360–363
  8. Kraft A, Weindel K, Ochs A, et al.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178–187
  9. Yamamoto S, Konishi I, Mandai M, et al.  Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms (correlation with clinicopathology and patient survival, and analysis of serum VEGF levels). Br J Cancer. 1997;76:1221–1227
  10. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–1225
  11. Chen CA, Cheng WF, Lee CN, et al.  Serum vascular endothelial growth factor in epithelial ovarian neoplasms (correlation with patient survival). Gynecol Oncol. 1999;74:235–240
  12. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 2000;20:5109–5112
  13. Nagy JA, Masse EM, Herzberg KT, et al.  Pathogenesis of ascites tumour growth (vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation). Cancer Res. 1995;55:360–368
  14. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039
  15. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 2000;16:445–454
  16. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174
  17. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis (an imbalance of positive and negative regulation). Cancer Res. 1991;51:5054s–5059s
  18. Matrisian LM. Cancer biology (extracellular proteinases in malignancy). Curr Biol. 1999;9:R776–R778
  19. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–3119
  20. Scorilas A, Karameris A, Arnogiannaki N, et al.  Overexpression of matrix-metalloproteinase-9 in human breast cancer (a potential favourable indicator in node-negative patients). Br J Cancer. 2001;84:1488–1496
  21. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer (prognostic markers and therapeutic targets). Int J Cancer. 2002;99:157–166
  22. Garzetti GG, Ciavattini A, Lucarini G, et al.  Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumours. Cancer. 1999;85:2219–2225
  23. Lengyel E, Schmalfeldt B, Konik E, et al.  Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001;82:291–298
  24. Davidson B, Goldberg I, Gotlieb WH, et al.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 1999;17:799–808
  25. Giavazzi R, Garofalo A, Ferri C, et al.  Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:985–992
  26. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA) (structure, control of expression and biological functions). Pharmacol Ther. 1993;59:329–341
  27. Khokha R. Suppression of the tumourigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst. 1994;86:299–304
  28. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases (structure, regulation and biological functions). Eur J Cell Biol. 1997;74:111–122
  29. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer—a predictor of tumour stage. Br J Cancer. 1997;76:805–811
  30. Yoshikawa T, Saitoh M, Tsuburaya A, et al.  Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer. 1999;86:1929–1935
  31. F.I.G.O. News . Int J Gynecol Obstet. 1989;28:189–193
  32. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer Oct. 2002;2:727–739
  33. Cooper BC, Ritchie JM, Broghammer CL, et al.  Preoperative serum vascular endothelial growth factor levels (significance in ovarian cancer). Clin Cancer Res. 2002;8:3193–3197
  34. Gadducci A, Ferdeghini M, Fanucchi A, et al.  Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer (relationship with prognostic variables and clinical outcome). Anticancer Res. 1999;19:1401–1405
  35. Verheul HM, Hoekman K, Luykx-de Bakker S, et al.  Platelet (transporter of vascular endothelial growth factor). Clin Cancer Res. 1997;3:2187–2190
  36. Banks RE, Forbes MA, Kinsey SE, et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets (significance for VEGF measurements and cancer biology). Br J Cancer. 1998;77:956–964
  37. Wynendaele W, Derua R, Hoylaerts MF, et al.  Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers (a key to study an angiogenic marker in vivo?). Ann Oncol. 1999;10:965–971
  38. Monreal M, Fernandez-Llamazares J, Pinol M, et al.  Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916–918
  39. Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol. 1998;19:82–84
  40. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet. 1998;352:1775–1777
  41. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 2000;96:4216–4221
  42. Polette M, Gilbert N, Stas I, et al.  Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 1994;424:641–645
  43. Huang S, Van Arsdall M, Tedjarati S, et al.  Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94:1134–11342
  44. Lane WJ, Dias S, Hattori K, et al.  Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000;96:4152–4159
  45. Campo E, Tavassoli FA, Charonis A, Stetler-Stevenson WG, Liotta LA, Merino MJ. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumours of the ovary. Am J Pathol. 1992;6:500–507
  46. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000;36:1258–1268
  47. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors (markers for malignant potential). Br J Cancer. 1994;70:506–512
  48. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999;84:44–48

PII: S0959-8049(03)00427-1

doi: 10.1016/S0959-8049(03)00427-1

European Journal of Cancer
Volume 39, Issue 13 , Pages 1948-1956 , September 2003

Article Tools

* Image Usage & Resolution